Palvella Therapeutics (NASDAQ:PVLA) Given Buy Rating at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note issued to investors on Monday,Benzinga reports. Chardan Capital currently has a $210.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. Raymond James Financial restated a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a report on Tuesday, February 24th. BTIG Research increased their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. Finally, HC Wainwright boosted their price target on Palvella Therapeutics from $200.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $184.87.

Palvella Therapeutics Trading Up 3.3%

Shares of PVLA stock opened at $126.05 on Monday. The firm’s fifty day moving average price is $101.50 and its two-hundred day moving average price is $86.93. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $151.18. The firm has a market capitalization of $1.49 billion, a P/E ratio of -47.93 and a beta of -0.31.

Insider Transactions at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elaine J. Heron purchased 2,400 shares of the stock in a transaction on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the transaction, the director owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. The trade was a 5.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is owned by company insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Group One Trading LLC boosted its stake in shares of Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the period. Archer Investment Corp bought a new stake in Palvella Therapeutics in the 3rd quarter valued at $28,000. Russell Investments Group Ltd. bought a new stake in Palvella Therapeutics in the 3rd quarter valued at $36,000. China Universal Asset Management Co. Ltd. acquired a new stake in Palvella Therapeutics during the 4th quarter valued at $167,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics during the second quarter worth $37,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.